CCM
DNTH icon

CAAS Capital Management’s Dianthus Therapeutics DNTH Stock Holding History

CAAS Capital Management’s Portfolio DNTH Stock Details DNTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-3,125
Closed -$376K – 507
2020
Q2 		$376K Buy
+3,125
New +$440K 0.01% 335

Other funds holding DNTH

TGI
TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

CAAS Capital Management's DNTH Position: Q3 2020 in Review

CAAS Capital Management sold out of Dianthus Therapeutics (DNTH) in Q3 2020, closing a stake of 3,125 shares — an estimated $376K sold.

CAAS Capital Management first reported a position in DNTH in Q2 2020 and held it in 1 quarter. The position peaked at $376K in Q2 2020. 94 funds tracked by Wall St. Rank hold DNTH as of Q3 2020.

  • CAAS Capital Management reported no remaining Dianthus Therapeutics position as of Q3 2020 after selling out during the quarter.
  • CAAS Capital Management sold 3,125 Dianthus Therapeutics shares in Q3 2020, an estimated $376K.
  • CAAS Capital Management first reported a position in Dianthus Therapeutics in Q2 2020 and held it in 1 quarter.
  • CAAS Capital Management's Dianthus Therapeutics position peaked at $376K in Q2 2020.
  • 94 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q3 2020.

Based on CAAS Capital Management's 13F filing for Q3 2020, filed 9 Nov 2020.